|By Marketwired .||
|May 6, 2014 07:00 AM EDT||
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/06/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Harold E. "Barry" Selick, Ph.D., Chief Executive Officer of Threshold and Cary L. Queen, Ph.D., President of Galaxy Biotech, have been jointly named as finalists for the European Inventor Award 2014 in the "Non-European Countries" category. Their nomination is in recognition of their work while at Protein Design Labs, Inc. ("PDL") in inventing the humanized monoclonal antibody technology that is embodied in numerous therapeutics such as Avastin® and Herceptin®, as well as Zenapax®, which was the first humanized antibody therapeutic that was approved as a drug by the U.S. Food & Drug Administration (FDA) and which was PDL's first product. Dr. Queen, who led the antibody humanization program, was the co-founder and head of research at PDL while Dr. Selick was a staff scientist working with him at the time. The final award ceremony at which the winners in each of 5 different categories will be announced will take place in Berlin, Germany, on June 17, 2014.
About the European Inventor Award
The European Inventor Award pays tribute to the creativity of inventors the world over, who use their technical, scientific and intellectual skills to make a real contribution to technological progress and economic growth and so improve people's daily lives. Launched by the European Patent Office (EPO) in 2006, the award gives inventors the recognition they deserve, and helps to encourage creativity and innovation. Any member of the public can nominate an inventor for the European Inventor Award. The selection process relies on the hard work of EPO experts and an independent international jury that evaluates innovations not only on their technological originality but also on their economic and social impact.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
E-mail: [email protected]
Jan. 16, 2017 06:45 PM EST Reads: 3,480
Jan. 16, 2017 06:00 PM EST Reads: 329
Jan. 16, 2017 05:00 PM EST Reads: 3,981
Jan. 16, 2017 03:30 PM EST Reads: 4,815
Jan. 16, 2017 03:15 PM EST Reads: 320
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
Jan. 16, 2017 03:15 PM EST Reads: 409
Jan. 16, 2017 02:30 PM EST Reads: 1,544
Jan. 16, 2017 02:15 PM EST Reads: 5,257
Jan. 16, 2017 01:45 PM EST Reads: 3,588
Jan. 16, 2017 01:30 PM EST Reads: 3,305
Jan. 16, 2017 01:00 PM EST Reads: 3,634
Jan. 16, 2017 01:00 PM EST Reads: 1,025
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
Jan. 16, 2017 12:30 PM EST Reads: 5,469
Jan. 16, 2017 12:30 PM EST Reads: 5,005
Jan. 16, 2017 12:30 PM EST Reads: 3,353